Financial Avengers Inc. reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 20.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200 shares of the pharmaceutical company’s stock after selling 50 shares during the quarter. Financial Avengers Inc.’s holdings in Vertex Pharmaceuticals were worth $58,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of VRTX. TFC Financial Management grew its position in Vertex Pharmaceuticals by 58.0% in the 2nd quarter. TFC Financial Management now owns 109 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 40 shares in the last quarter. Trust Co. of Vermont purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $33,000. Ronald Blue Trust Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $34,000. First Personal Financial Services purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $36,000. Finally, James Investment Research Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $37,000. 90.96% of the stock is owned by institutional investors and hedge funds.
In other news, Director Yuchun Lee sold 442 shares of the business’s stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $312.17, for a total value of $137,979.14. Following the transaction, the director now owns 1,875 shares of the company’s stock, valued at $585,318.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP David Altshuler sold 1,303 shares of the company’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $303.04, for a total transaction of $394,861.12. Following the transaction, the executive vice president now owns 36,077 shares of the company’s stock, valued at $10,932,774.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yuchun Lee sold 442 shares of the company’s stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $312.17, for a total value of $137,979.14. Following the transaction, the director now directly owns 1,875 shares in the company, valued at approximately $585,318.75. The disclosure for this sale can be found here. Corporate insiders own 0.40% of the company’s stock.
Wall Street Analyst Weigh In
Vertex Pharmaceuticals Stock Performance
VRTX traded up $0.23 during trading on Wednesday, hitting $313.80. 165,178 shares of the stock were exchanged, compared to its average volume of 1,365,505. The firm has a market capitalization of $80.55 billion, a P/E ratio of 24.73, a PEG ratio of 1.94 and a beta of 0.46. Vertex Pharmaceuticals Incorporated has a 1-year low of $225.01 and a 1-year high of $324.75. The stock has a fifty day moving average price of $303.94 and a two-hundred day moving average price of $296.57. The company has a quick ratio of 4.55, a current ratio of 4.70 and a debt-to-equity ratio of 0.03.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last released its quarterly earnings results on Thursday, October 27th. The pharmaceutical company reported $3.62 EPS for the quarter, topping the consensus estimate of $3.31 by $0.31. The company had revenue of $2.33 billion for the quarter, compared to analyst estimates of $2.23 billion. Vertex Pharmaceuticals had a return on equity of 29.65% and a net margin of 37.62%. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 13.02 earnings per share for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.